Sunshine Hospital
Sunshine Hospital
St Albans, Victoria, Australia18 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive | HER2-positive Breast Cancer | Recruiting | Phase 2 / Phase 3 | 2026-10-06 | NCT07413939 | |
| A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05797610 | |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT05485961 | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Active, not recruiting | Phase 3 | 2026-09-14 | NCT06065748 | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-11 | NCT04576455 | |
| Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, neoplasm | Recruiting | Phase 3 | 2026-09-01 | NCT02582697 | |
| A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05593094 | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-17 | NCT04546009 | |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-07-09 | NCT02319837 | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-06-17 | NCT04961996 | |
| Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-05-06 | NCT04136353 | |
| Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02446444 | |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-04-13 | NCT04650581 | |
| SODium BICarbonate for Metabolic Acidosis in the ICU | Acid-Base Imbalance, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, acidosis disorder, metabolic acidosis, metabolic disease | Active, not recruiting | Phase 3 | 2026-03-27 | NCT05697770 | |
| The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, autoimmune disease, cardiovascular disorder, diabetes mellitus, diabetic kidney disease, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, glucose metabolism disease, immune system disorder, kidney disorder, metabolic disease, retinal disorder, type 1 diabetes mellitus, urinary system disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-01-20 | NCT01320345 | |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, Neoplasms by Histologic Type, Neoplasms by Site, agammaglobulinemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, inborn error of immunity, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, plasma cell neoplasm | Recruiting | Phase 2 / Phase 3 | 2024-04-19 | NCT05678621 | |
| The TEAM Long-Term Cohort Study (A Sub-study of TEAM(III)) | Critical Illness, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Enrolling by invitation | Not stated | 2022-03-28 | NCT05298982 |